Bacil Pharma reports standalone nil net profit/loss in the September 2022 quarter

Bacil Pharma reports standalone net loss of Rs 0.08 crore in the September 2021 quarter

The creamy layer - amongst the top performing stocks

Seems to be overvalued vs the market average

Lagging behind the market in financials growth

Average profitability - not good, not bad

Not a good time to consider, stock is in the overbought zone

The stock has a moderate number of red flags

Bacil Pharma is engaged in the business of manufacturing of pharmaceuticals, medicinal chemicals and botanical products.